Thiazolidinedione

This page covers all Thiazolidinedione drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PPAR-γ (Peroxisome proliferator-activated receptor gamma), PPARγ, PPAR-γ.

Targets

PPAR-γ (Peroxisome proliferator-activated receptor gamma) · PPARγ · PPAR-γ

Marketed (1)

• Placebo then Pioglitazone · Medical University of South Carolina · Diabetes
  Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.

Phase 3 pipeline (5)

• Comparator: Rosiglitazone · Merck Sharp & Dohme LLC · Diabetes
  Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose levels.
• Matching placebo to pioglitazone · Merck Sharp & Dohme LLC · Diabetes
  This is a placebo control arm matching pioglitazone, a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity.
• Rosiglitazone (BRL49653C) · GlaxoSmithKline · Diabetes
  Rosiglitazone activates PPARγ, a nuclear receptor that regulates glucose and lipid metabolism.
• rosiglitazone (4 mg)/day · National Cheng-Kung University Hospital · Diabetes
  Rosiglitazone activates PPAR-γ, leading to increased insulin sensitivity and glucose uptake in adipose tissue.
• Comparator: placebo to pioglitazone · Merck Sharp & Dohme LLC · Diabetes
  Pioglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose levels.